Muscle-Specific Deletion of Rictor Impairs Insulin-Stimulated Glucose Transport and Enhances Basal Glycogen Synthase Activity\†

Anil Kumar,¹* Thurl E. Harris,¹ Susanna R. Keller,² Kin M. Choi,¹†
Mark A. Magnuson,³ and John C. Lawrence, Jr.¹‡

Department of Pharmacology, University of Virginia Health System, Charlottesville, Virginia 22908;¹ Internal Medicine, Division of Endocrinology, University of Virginia Health System, Charlottesville, Virginia 22908;² and Center for Stem Cell Biology and Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee 37232³

Received 5 August 2007/Returned for modification 31 August 2007/Accepted 16 October 2007

Rictor is an essential component of mTOR (mammalian target of rapamycin) complex 2 (mTORC2), a kinase complex that phosphorylates Akt at Ser473 upon activation of phosphatidylinositol 3-kinase (PI-3 kinase). Since little is known about the role of either rictor or mTORC2 in PI-3 kinase-mediated physiological processes in adult animals, we generated muscle-specific rictor knockout mice. Muscle from male rictor knockout mice exhibited decreased insulin-stimulated glucose uptake, and the mice showed glucose intolerance. In muscle lacking rictor, the phosphorylation of Akt at Ser473 was reduced dramatically in response to insulin. Furthermore, insulin-stimulated phosphorylation of the Akt substrate AS160 at Thr642 was reduced in rictor knockout muscle, indicating a defect in insulin signaling to stimulate glucose transport. However, the phosphorylation of Akt at Thr308 was normal and sufficient to mediate the phosphorylation of glycogen synthase kinase 3 (GSK-3). Basal glycogen synthase activity in muscle lacking rictor was increased to that of insulin-stimulated controls. Consistent with this, we observed a decrease in basal levels of phosphorylated glycogen synthase at a GSK-3/protein phosphatase 1 (PP1)-regulated site in rictor knockout muscle. This change in glycogen synthase phosphorylation was associated with an increase in the catalytic activity of glycogen-associated PP1 but not increased GSK-3 inactivation. Thus, rictor in muscle tissue contributes to glucose homeostasis by positively regulating insulin-stimulated glucose uptake and negatively regulating basal glycogen synthase activity.

Insulin signaling is essential for glucose homeostasis. In muscle, insulin promotes both glucose uptake and the incorporation of glucose into glycogen, processes that contribute greatly to insulin-mediated glucose disposal after a meal (49). Defects in glucose uptake and glycogen synthesis, which occur in diabetes, are implicated in the development of hyperglycemia and, over time, in other complications (12). Both glucose transport (49) and glycogen synthase activation (31) are considered to be rate-limiting steps for glycogen synthesis in skeletal muscle. In myocytes, insulin signaling enhances glucose entry into the cell by translocating the glucose transporter GLUT4 from intracellular sites to the cell surface (27). In addition, insulin signaling enhances the incorporation of glucose into glycogen by activating glycogen synthase after inducing its dephosphorylation (38).

Many of the physiological processes regulated by insulin signaling are mediated by phosphatidylinositol 3-kinase signaling via the serine/threonine (Ser/Thr) kinase Akt (PKB) (54). Although the precise mechanisms by which insulin stimulates glucose uptake remain to be established, direct Akt substrates, like AS160 (25), may play an important role by regulating GLUT4 translocation to the cell surface (21). Activation of glycogen synthase by insulin involves phosphorylation and inactivation of the α and β isoforms of the Akt substrate glycogen synthase kinase 3 (GSK-3) at Ser9 and Ser21, respectively (10). In the basal state, GSK-3 phosphorylates glycogen synthase at sites 3a, 3b, 3c, and 4, corresponding to Ser641, -645, -649, and -653 in the COOH terminus, and inactivates glycogen synthase (38, 39). Phosphorylated GSK-3 target sites in glycogen synthase are actively dephosphorylated in response to insulin by glycogen-associated protein phosphatase 1 (PP1) (35).

Insulin signaling rapidly activates Akt by phosphorylation at two residues, Thr308 and Ser473, both of which are required for full activation of this kinase in vitro (1, 3). Thr308, which resides in the activation loop of Akt, is phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) (2). A previously unknown kinase, similarly termed PDK2, had been proposed to mediate the phosphorylation of Ser473 in the COOH-terminal hydrophobic motif of Akt. Recent studies have convincingly established that PDK2 is the mTOR (mammalian target of rapamycin) complex 2 (mTORC2) (20, 44).

mTOR is a Ser/Thr kinase that has long been known to regulate cell growth and proliferation in response to insulin, nutrients, and growth factors. Studies over the past few years have shown that mTOR is the catalytic subunit of at least two distinct multiprotein complexes (55). mTOR complex 1 (mTORC1), formed by mTOR interaction with raptor, mLST8 (55), and PRAS40 (55), phosphorylates S6K1 and 4EBP1 in response to insulin and growth factor stimulation and is sensitive to rapamycin inhibition (55). On the other hand, mTORC2, which is composed of rictor (rapamycin-insensitive

* Corresponding author. Mailing address: Department of Pharmacology, University of Virginia Health System, P.O. Box 800735, 1300 Jefferson Park Ave., Charlottesville, VA 22908. Phone: (434) 924-1582. Fax: (434) 992-3878. E-mail: ak4p@virginia.edu.
† Present address: Primanova Biosciences, Inc., 3235 Route 112, Medford, NY 11763.
‡ Died on 19 December 2006.
† Published ahead of print on 29 October 2007.
companion of mTOR, mLST8, mSin1, and mTORC2, is acutely insensitive to rapamycin (23, 55). Disruption of mTORC2 in mice by homozygous deletion of rictor (16, 48), mLST8 (16), or mSin1 (23) causes embryonic lethality. Therefore, the physiological role of mTORC2 could not be established. Studies using mouse embryonic fibroblasts (MEFs) that lack these genes have demonstrated that loss of mTORC2 eliminates Akt Ser473 phosphorylation. This results in the inhibition of insulin signaling to some, but not all, Akt substrates (16, 23, 48).

In this study we used mice containing a conditional rictor allele (Rictor<sup>flox<sup>lox</sup></sup>) (48) to eliminate rictor in a muscle-specific manner. These mice were used to determine the role of mTORC2 in insulin-mediated glucose metabolism in the skeletal muscle of adult animals.

**MATERIALS AND METHODS**

**Generation of MRic<sup>−/−</sup> mice.** Rictor<sup>flox/WT</sup> mice (84.9% C57BL6/J, 15.1% 129s6) (48) were crossed with muscle creatine kinase (MCK)-Cre<sup>−/−</sup> transgenic mice (6) to obtain heterozygous MCK-Cre<sup>+/−</sup> Rictor<sup>flox/WT</sup> offspring (where WT is wild type) in the F1 generation. These heterozygous mice were crossed with Rictor<sup>flox/lox</sup> mice to obtain the muscle-specific rictor knockout mice with genotype MCK-Cre<sup>−/−</sup> Rictor<sup>flox/lox</sup> (referred to in the paper as MRic<sup>−/−</sup> or knockout) in the F2 generation. The MRic<sup>−/−</sup> mice were then crossed with Rictor<sup>flox/lox</sup> mice to generate the MRC<sup>−/−</sup> and their MCK-Cre<sup>−/−</sup> Rictor<sup>flox/lox</sup> littermates (referred to in the paper as MRic<sup>−/−</sup> or wild type) in the F3 and following generations. Age-matched MRic<sup>−/−</sup> and MRic<sup>−/−</sup> mice of both sexes were studied at 3 to 5 months. For all mice used, the genotype was sexed by homozygous deletion of rictor (16, 48), mLST8 (16), or mLST8<sup>−/−</sup> (17) containing 0.1% Tween 20 and were centrifuged at 1,000 g for 20 min at 4°C to pellet insoluble material. The protein concentration of the supernatant was determined. For immunoblotting, muscle extract samples (containing 25 to 100 µg of total protein) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 7.5% or 10% polyacrylamide gels before proteins were transferred electrophoretically to Immobilon membranes (Millipore). After incubation with different antibodies, the membranes were washed, and antibody binding was detected using alkaline phosphatase-conjugated secondary antibodies and Tropix reagent (PerkinElmer Life Sciences). Relative signal intensities of bands in immunoblots were determined by scanning laser densitometry of X-ray film or by use of a FujiFilm LAS 3000 charge-coupled device camera system with ImageQuant software (Molecular Dynamics). The level of phosphorylation of a particular protein was obtained after correcting for differences in the total level for the corresponding protein.

For PP1 activity measurements, extracts were prepared in 50 mM Tris-HCl (pH 7.5) buffer containing 0.1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1 mM Na<sub>2</sub>SO<sub>4</sub>-Lys-chloromethyl ketone - HCI (TLCK), 2 mM benzamidine, 0.5 mM PMSF, 50 mM β-mercaptoethanol, 4 mM odaic acid, 10 µg/ml leupeptin, and 2% glycogen.

**Measurements of glycogen synthase activity.** Muscle extracts were prepared by homogenizing the powdered muscles on ice using a tissue grinder (Teflon glass) in 800 µl of homogenization buffer (50 mM Tris-HCl [pH 7.8], 100 mM NaCl, 10 mM EDTA). The homogenates were centrifuged for 5 min at 10,000 x g, and the supernatants were retained for analyses. The protein content of the extracts was measured and adjusted to a concentration of 1 mg/ml by adding homogenization buffer. Glycogen synthase activity was measured by the method of Thomas et al. (47). Incubation solutions (60 µl) containing 30 µg/mg of total protein, 20 mM glucose, 5 mM Na<sub>2</sub>HPO<sub>4</sub>, 2.5 U/ml hexokinase, and 1 µCi/60 µl [1-14C]glucose (0.07 µCi/ µl; Amersham Pharmacia Biotech) and incubated without or with 10 mM glucose-6-phosphate (G-6P) at 30°C for 20 min. G-6P is an allosteric activator of glycogen synthase and can activate even phosphorylated and inactive glycogen synthase. It is therefore used to determine total glycogen synthase activity. The glycogen synthase activity ratio was determined by dividing the activity measured without added G-6P by the activity measured in the presence of 10 mM G-6P (total activity).

**Determination of 2-deoxy-glucose uptake into muscles.** 2-Deoxy-glucose uptake in EDL muscle isolated from male mice fasted overnight was measured by a method described previously (4). Briefly, EDL muscles were incubated at 37°C in Krebs-Henseleit buffer either without or with 20 mM/ml insulin for 15 min and then transferred to the same buffer (10 µl/muscle) containing 0.5 mM 2-deoxy-[1,2-3H]glucose (1 µCi/ml) and 10 mM [1,2-14C] mannitol (0.1 µCi/ml). After stimulation without and with insulin for 15 min, incubations were terminated by washing the muscles in Krebs-Henseleit buffer at 4°C and freezing them in liquid nitrogen. The muscles were weighed and lysed in 1 N HCl at 65°C for 30 min. The samples were centrifuged at 13,000 x g, and the supernatant was transferred to a fresh tube and neutralized with 1 N NaOH. The radioactivity in the sample was determined in a liquid scintillation counter, set for counting dual labels. The radioactivity values presented (µmol/ml intracellular water/h) for glucose uptake were correct for the extracellular space, which was estimated from the amount of [14C]mannitol recovered in the lysed muscles.

**Glycogen content determination.** Total cellular glycogen content was determined by modification of a method described by Pasonneau and Luderdale (36). Muscles were weighed (20 to 30 mg) and homogenized in 10 volumes of 0.03 N HCl. The homogenates were placed into boiling water for 5 min. The extracts (5 µl and/or 10 µl) were incubated with or without 50 ng amylgluco- sidase per sample in 100 µl of 0.2 M sodium acetate, pH 4.8, at room temperature for 3 h and vortexed regularly to avoid sedimentation. Samples were then incubated with an assay cocktail (0.1 mM Tris-HCl [pH 8.0], 0.3 mM ATP, 6 mM MgCl<sub>2</sub>, 5 mM dithiothreitol, 60 µM NAD<sup>+</sup>, 2.5 U/ml hexokinase, and 1 µg/ml G-6P dehydrogenase) for 30 min at room temperature. Changes in fluorescence, as a result of NADPH production, were determined using a fluorometer. Reaction blank values were determined as the fluorescence of samples before enzymatic treatment with amylglucosidase.

**Preparation of total membrane/glycogen pellet.** Muscle samples were homogenized with a polytron homogenizer in a HEPES-EDTA-sucrose (HES) buffer containing 20 mM HEPES (pH 7.5 at 4°C), 5 mM EDTA, 250 mM sucrose, 4 mM Na<sub>2</sub>SO<sub>4</sub>, 2 µg/ml pepstatin, 1 µg/ml leupeptin, and 10 µg/ml aprotinin. The homogenates were subjected to low-speed centrifugation, and the supernatant was discarded. The postnuclear supernatant was then centrifuged at 220,000 x g for 4.5 h at 4°C. The pellet containing the total membrane/
glycogen fraction was resuspended in HES buffer and used to determine the levels of GLUT1, GLUT4, RGL, PPIα, PPIβ, glycogen synthase, and phosphorylated glycogen synthase at its Ser641 residue by immunoblotting or used to measure the glycogen-associated PP1 activity.

**Determination of PP1 activity.** 32P-labeled glycogen phosphorylase was prepared by a method described by Cohen et al. (9). Muscle extracts or glycogen pellets (3 μg protein/reaction) prepared by the method described above were preincubated with 4 nM of okadaic acid for 2 min at 30°C in PP1 assay buffer containing 50 mM Tris·HCl (pH 7.5), 0.1 mM EDTA, and 25 mM β-mercaptoethanol. 32P-labeled glycogen phosphorylase (15 μg/reaction) was incubated in PP1 assay buffer with 5 mM caffeine and 4 nM okadaic acid at 30°C for 5 min before being mixed with the okadaic acid-treated muscle extract. The mixture was incubated at 30°C for 10 min, and the level of phosphate released was determined by a method described previously (34).

**Determination of GSK-3 activity.** GSK-3 activity in the muscle extracts was determined using a muscle glycogen synthase peptide as described previously (40).

**Intraperitoneal glucose/insulin tolerance tests.** Mice were fasted overnight before intraperitoneal injection of 1 mg of glucose/kg of body weight. The glucose solutions were prepared in 0.9% saline and warmed to 37°C prior to injections. Blood was sampled from the tail vein before (time zero) and 15, 30, 45, and 120 min after glucose injection. For insulin tolerance tests, random-fed animals were injected intraperitoneally with insulin (Novolin, 0.75 U/kg body weight) at about 2 pm. Blood glucose was sampled from the tail vein before injection (time zero) and 15, 30, 45, and 60 min after insulin injection. Blood glucose levels were determined using a glucometer (One Touch FastTake; LifeScan).

**Miscellaneous.** Nonesterified fatty acid levels were measured in serum obtained from overnight-fasted animals by using a NEFA-C kit from Wako Chemicals.

**Animals, antibodies, and chemicals.** The MCK-Cre transgenic mice were generously provided by C. Ronald Kahn (Joslin Diabetes Center). The anti-riktor antibody, the pan-actin antibody, and all phospho-specific antibodies except the anti-rictor antibody, the pan-actin antibody, and all phospho-specific antibodies except the anti-rictor antibody were generously provided by A. DePaoli-Roach (University of Indiana, Indianapolis). The pan-actin antibody was raised in rabbits to a 1-kb DNA ladder (Invitrogen) was used as the molecular mass marker (lane 1). (B) Tissue extracts prepared from skeletal muscle and adipose tissue were subjected to SDS-PAGE and were immunoblotted with anti-riktor antibodies (top). The mTOR immunoblot shown in the bottom panel served as the loading control in these experiments.

**RESULTS**

**Muscle-specific deletion of rictor in mice.** Mice with a muscle-specific deletion of rictor (MRic−/− mice) were obtained by crossing Rictorfl(o×/o) and MCK-Cre transgenic mice. MCK-Cre-mediated excision of the floxed exon 3 (97 bp) in the rictor gene results in a tissue-specific deletion of rictor, as verified by analyzing RNA from hind limb muscles of MRic+/+ and MRic−/− mice, respectively (Fig. 1A, lanes 2 and 3). RNA isolated from muscle of MRic−/− mice showed a 413-bp (Fig. 1A, lane 3) product, whereas a 510-bp product was seen by using muscle from MRic+/+ mice (Fig. 1A, lane 2). The detection of only a 510-bp product in adipose tissue RNA of both MRic+/+ and MRic−/− mice demonstrates the specificity of MCK-Cre-mediated gene deletion (Fig. 1A, lanes 4 and 5). To confirm that the frameshift in the rictor mRNA eliminates protein expression, MRic−/− mice extracts from both hind limb muscle and adipose tissue were immunoblotted with anti-riktor antibody (Fig. 1B, top). Rictor protein level was reduced by ~90% in muscle, whereas it was normal in adipose tissue, of MRic−/− mice. Thus, both RNA and protein analyses demonstrate the efficient and specific ablation of rictor gene expression in skeletal muscle of MRic−/− mice. The MRic−/− mice were born at the expected Mendelian ratio and did not display any apparent defects in fertility or maturation (data not shown).

**Rictor ablation in muscle decreases in vivo insulin-stimulated phosphorylation of Akt Ser473 but not Thr308. mTORC2 phosphorylates Akt at Ser473, and this phosphorylation has been proposed to determine phosphorylation at Thr308 (44). To evaluate whether rictor plays a role in Akt Ser473 and Thr308 phosphorylation in vivo, hind limb muscle extracts prepared from saline- (basal) and insulin-injected MRic+/+ and MRic−/− mice were immunoblotted with phospho-Akt Ser473 and phospho-Thr308 Akt antibodies. Insulin caused a 10- to 15-fold increase in the phosphorylation of Akt at Ser473 in MRic+/+ muscles (Fig. 2A and B) compared to the level in muscles from saline-injected MRic+/+ mice. However, in MRic−/− muscles, the insulin-stimulated increase in Akt Ser473 phosphorylation was less than twofold, corresponding to an approximately 85% reduction in the level of Ser473-phosphorylated Akt compared to the level in insulin-injected MRic+/+ muscles (Fig. 2A and B). Interestingly, in MRic−/− muscles Akt was phosphorylated at Thr308 (Fig. 2A and C). Phosphorylation at this site in Akt was even slightly increased to approximately 85% reduction in the level of Ser473-phosphorylated Akt compared to the level in insulin-injected MRic+/+ muscles (Fig. 2A and C). The same extracts showed similar levels of expression of Akt in muscles of both genotypes (Fig. 2A).

To determine whether the impaired Akt Ser473 phosphorylation in MRic−/− mice affects insulin signaling downstream of Akt, we assessed phosphorylation of Thr389 in S6K1, a target of Akt, we assessed phosphorylation of Thr389 in S6K1, a target of Akt.
mTORC1. While significantly increased in saline-injected MRic<sup>−/−</sup> mice, the levels of phosphorylation of S6K1 Thr389 were similar in insulin-treated MRic<sup>+/+</sup> and MRic<sup>−/−</sup> mice (Fig. 2D and E), and the total amount of S6K1 was unchanged in MRic<sup>−/−</sup> mice (Fig. 2D). Moreover, Akt-mediated FoxO1 phosphorylation at Thr24 was reduced in rictor knockout MEFs (16).

In saline-injected MRic<sup>−/−</sup> muscle, FoxO1 Thr24 phosphorylation was increased compared to the level in saline-injected MRic<sup>++</sup> mice (Fig. 2D and F). Insulin treatment did not further induce FoxO1 phosphorylation in MRic<sup>−/−</sup> muscles but caused about a threefold increase in MRic<sup>+/+</sup> muscles (Fig. 2D and F). Since insulin is known to stimulate phosphorylation of Akt substrates GSK-3α and β at Ser21 and Ser9 residues (10), we tested whether this response was impaired in muscles from MRic<sup>−/−</sup> mice. Compared to levels in muscles obtained from saline-injected MRic<sup>++</sup> mice, the phosphorylation levels of both Ser21 and Ser9 in GSK-3α and β were increased 1.5- to 2-fold in muscles from saline-injected MRic<sup>−/−</sup> mice (Fig. 2D and G), and insulin treatment increased the phosphorylation at both of these residues in GSK-3α and β to similar extents in the muscle extracts of MRic<sup>+/+</sup> and MRic<sup>−/−</sup> mice (Fig. 2D and G).

**Basal glycogen synthase activity is increased in MRic<sup>−/−</sup> muscles.** To determine whether the loss of rictor in skeletal muscle affects glycogen synthesis, we measured the glycogen synthase activity ratio in MRic<sup>−/−</sup> muscles. The glycogen synthase activity ratio in skeletal muscle extracts prepared from saline- and insulin-treated MRic<sup>+/+</sup> and MRic<sup>−/−</sup> mice is shown in Fig. 3A. In MRic<sup>+/+</sup> mice, the insulin-stimulated glycogen synthesis activity ratio was increased ~2-fold (0.168 ± 0.01 versus 0.088 ± 0.007, n = 7 per group, P < 0.0003), as previously reported (32, 47). Muscle from saline-injected MRic<sup>−/−</sup> mice showed a glycogen synthase activity ratio ~80% higher than that of muscles from saline-injected wild-type animals (0.151 ± 0.017 in MRic<sup>−/−</sup> versus 0.088 ± 0.009 in MRic<sup>+/+</sup> mice, n = 6 to 7 per group, P < 0.004). Furthermore, insulin-stimulated glycogen synthase activity in MRic<sup>−/−</sup> muscles was similar to those in muscles from saline-injected MRic<sup>−/−</sup> and insulin-injected MRic<sup>+/+</sup> mice (0.148 ± 0.012 in insulin-injected versus 0.151 ± 0.017 in saline-injected MRic<sup>−/−</sup> mice, n = 5 to 6 per group). Using the same muscle extracts, we also assessed the phosphorylation of glycogen synthase at Ser641 in muscle extracts from saline-injected MRic<sup>−/−</sup> mice and insulin-injected MRic<sup>+/+</sup> mice after insulin treatment (Fig. 3B, bottom). The total amount of glycogen synthase in extracts from MRic<sup>−/−</sup> muscles was identical to that seen in MRic<sup>+/+</sup> muscles.
When the same muscle extracts were tested for glycogen phosphorylase activity, no significant difference between the genotypes was detected (data not shown). Also, fasted MRic\(^{+/+}\)/H11001/H11001 and MRic\(^{+/+}\)/H11002/H11002 mice had similar muscle glycogen contents (3.50 ± 0.68 μmol of glucose/g tissue in MRic\(^{+/+}\)/H11001/H11001 mice versus 3.18 ± 1.18 μmol glucose/g tissue in MRic\(^{+/+}\)/H11002/H11002 mice, \(n = 5\) per group).

**Increased basal and insulin-stimulated glycogen synthase activity in ex vivo-incubated MRic\(^{+/+}\) muscle.** We next measured the glycogen synthase activity ratio in EDL muscle by incubation in the absence or presence of insulin ex vivo. Muscle from the MRic\(^{-/-}\) mice showed a higher basal glycogen synthase activity than muscle from MRic\(^{+/+}\) mice (Fig. 4A) (0.161 ± 0.011 versus 0.114 ± 0.010, \(n = 4\) per group, \(P < 0.025\)). In contrast to results from the in vivo experiments, insulin-stimulated glycogen synthase activity was ∼31% higher in MRic\(^{-/-}\) muscles than in MRic\(^{+/+}\) muscles (0.235 ± 0.011 versus 0.176 ± 0.010, \(n = 4\) per group, \(P < 0.006\)). Rapamycin had no effect on insulin-stimulated glycogen synthase activity in muscle from mice of either genotype. Since the MRic\(^{-/-}\) muscle incubated in the presence of rapamycin was devoid of both mTORC1 and mTORC2 activities, we conclude that activation of glycogen synthase in response to insulin is independent of both mTOR complexes.

To further assess the phosphorylation state of insulin signaling proteins, we performed additional immunoblotting experiments using protein extracts made from muscles incubated ex vivo (Fig. 4B). While insulin again failed to stimulate Akt Ser473 phosphorylation in the MRic\(^{+/+}\) muscles, unlike results from the in vivo experiments there was no increase in the basal phosphorylation of Akt at Thr308 (Fig. 4B) or GSK-3\(β\) at Ser9 (Fig. 4B and C). However, insulin treatment increased the

---

**FIG. 3.** Loss of rictor expression enhances basal glycogen synthase activity in muscle. (A) In vivo insulin-stimulated glycogen synthase activity in muscles of MRic\(^{+/+}\) and MRic\(^{-/-}\) mice. Glycogen synthase activity was measured using hind limb muscle extracts prepared from saline (-) or insulin (+)-injected mice in the absence and presence of G-6P (10 mM). The activity ratios are the activity measured in the absence of G-6P divided by that in the presence of G-6P (total activity) (means ± SE, \(n = 5\) to 7 per group; *, \(P < 0.004\); **, \(P < 0.00003\)). (B) Muscle extracts used for the glycogen synthase assay were resolved by SDS-PAGE and immunoblotted with phospho-specific glycogen synthase (P-S641 GS) antibodies and total glycogen synthase (GS) antibodies (top). Quantification of P-S641 GS immunoblots is shown in the bottom panel (\(n = 5\) per group).

**FIG. 4.** Ex vivo-incubated MRic\(^{-/-}\) muscle shows insulin-responsive glycogen synthase activity even with increased basal glycogen synthase activity. EDL muscles were incubated in Krebs-Henseleit buffer without (-) or with (+) insulin (100 mU/ml) for 30 min. The rapamycin-treated muscles were first incubated with rapamycin (200 nM final concentration) alone and then with rapamycin and insulin for 30 min. (A) Glycogen synthase activity was measured in EDL as described in the legend of Fig. 3A (means ± SE, \(n = 4\) per group; *, \(P < 0.025\); **, \(P < 0.006\)). (B) Protein extracts prepared from EDL muscles were subjected to SDS-PAGE and immunoblotted with phospho-specific antibodies to Akt, S6K1, GSK-3\(β\), and glycogen synthase and antibodies to actin and total glycogen synthase. (C) Quantification of GSK-3\(β\) Ser9 phosphorylation (means ± SE, \(n = 4\); *, \(P < 0.01\)) after normalization to actin. arb. units, arbitrary units.
increased levels of G-6P, an allosteric activator of glycogen synthase activity (Fig. 3A and Fig. 4A) was due, at least in part, to insulin-stimulated glucose uptake in MRic<sup>−/−</sup> muscles compared to MRic<sup>+/+</sup> muscles (n = 6, P < 0.04). The reduction in insulin-stimulated glucose uptake in muscles from MRic<sup>−/−</sup> mice could not be explained by changes in the levels of glucose transporters GLUT1 and GLUT4, as they were unaltered (Fig. 5B).

Since the lack of rictor in muscle causes both a reduction in insulin-stimulated glucose transport and an increase in basal glycogen synthase activity, we next sought to determine whether these defects are physiologically significant by performing intraperitoneal glucose tolerance tests with fasted male MRic<sup>−/−</sup> mice. The basal blood glucose concentration was the same in these animals as in the control mice (Fig. 5C). After a glucose bolus, the blood glucose concentrations were higher at 15, 30, and 60 min in MRic<sup>−/−</sup> mice; however, the observed difference in blood glucose concentrations of MRic<sup>−/−</sup> mice compared to those of wild-type mice was statistically significant only at 30 min (Fig. 5C) (189 ± 19 mg/dl in MRic<sup>−/−</sup> mice, n = 6, versus 285 ± 18 mg/dl in MRic<sup>+/+</sup> mice, n = 7; P < 0.004). Thus, in male MRic<sup>−/−</sup> mice the defects we observed in insulin signaling and glucose metabolism in muscle appear to cause impaired glucose tolerance. However, whole-body insulin sensitivity as measured by insulin tolerance test showed no significant difference (Fig. 5D). Serum nonesterified fatty acid levels were similar between MRic<sup>−/−</sup> and MRic<sup>+/+</sup> mice (n = 10 to 12 mice per group, 0.855 ± 0.08 meq/liter in MRic<sup>−/−</sup> mice and 0.810 ± 0.07 meq/liter in MRic<sup>−/−</sup> mice).

Defective insulin-stimulated AS160 Thr642 phosphorylation in MRic<sup>−/−</sup> muscles. Next, we tested the phosphorylation of AS160 at Thr642, a direct Akt substrate and a protein implicated in GLUT4 exocytosis (25). In the muscles of MRic<sup>−/−</sup> mice, there was an ~2-fold increase in AS160 Thr642 phosphorylation in response to insulin (Fig. 6). Although the AS160 phosphorylation at Thr642 was induced in muscles from insulin-treated MRic<sup>−/−</sup> mice, the increase was ~30% lower (1.7-fold) than in insulin-treated MRic<sup>+/+</sup> mice (Fig. 6). The defect in Akt-mediated AS160 phosphorylation could be partly responsible for the decreased insulin-stimulated glucose uptake in MRic<sup>−/−</sup> muscles.

Increased PP1 activity in glycogen pellets from MRic<sup>−/−</sup> muscles. To test whether PP1 plays a role in altered basal glycogen synthase activity in MRic<sup>−/−</sup> muscles, we next measured PP1 activity towards 32P-labeled glycogen phosphorylase in whole muscle extracts and glycogen pellets. Previously, it was demonstrated that loss of insulin-stimulated glucose transport in muscles from muscle-specific GLUT4 knockout mice (57) leads to increased basal glycogen synthase activity (26), a condition similar to that found with MRic<sup>−/−</sup> muscles. In muscle-specific GLUT4 knockout muscles, there was an increase in total PP1 activity when measured in vitro using 32P-labeled glycogen phosphorylase, due to upregulation in levels of R<sub>G</sub><sub>L</sub>, the muscle-specific regulatory subunit of PP1 (51), and another PP1 regulatory subunit, PTG. In contrast, in whole muscle extracts from MRic<sup>−/−</sup> mice, PP1 activity (Fig. 7A) as well as

![Image](http://mcb.asm.org/) on September 8, 2017 by guest
total level of $R_{GL}$ was unaltered (Fig. 7B). Among the four PP1 isoforms ($\alpha$, $\beta$, $\gamma_1$, and $\gamma_2$), PP1$\alpha$ and PP1$\beta$ are expressed in skeletal muscle (13). The levels of these PP1 isoforms were unchanged in whole muscle extracts from MRic$^{+/+}$ muscles (Fig. 7B). When measured in the muscle glycogen pellet, irrespective of whether the MRic$^{-/-}$ mice were injected with saline or insulin, PP1 activity was increased by 40 to 60% in the MRic$^{-/-}$ muscles compared to the level in MRic$^{+/+}$ muscles (Fig. 7C) ($0.72 \pm 0.03\text{ nmol}/10\min/\text{mg protein}$ versus $1.15 \pm 0.07\text{ nmol}/10\min/\text{mg protein}$ in saline-treated MRic$^{+/+}$ and MRic$^{-/-}$ mice, respectively, and $0.71 \pm 0.12\text{ nmol}/10\min/\text{mg protein}$ versus $1.37 \pm 0.12\text{ nmol}/10\min/\text{mg protein}$ in insulin-injected MRic$^{+/+}$ and MRic$^{-/-}$ mice, respectively; $n = 4$ to 5 per group; $P < 0.001$). Similarly to results seen with the whole muscle extracts (Fig. 3B), the levels of Ser641 phosphorylated glycogen synthase were decreased in the muscle glycogen pellets from saline-injected MRic$^{-/-}$ mice compared to levels in muscle glycogen pellets from saline-injected MRic$^{+/+}$ mice (Fig. 7D and E). The levels of glycogen synthase and $R_{GL}$ were unaltered in the glycogen pellets compared between treat-
ments and genotypes (Fig. 7D). Similarly, the levels of PP1α and PP1β were the same in glycogen pellets of MRic<sup>−/−</sup> and MRic<sup>+/+</sup> muscles (Fig. 7D).

Last, we measured GSK-3 activity in muscle extracts from saline- or insulin-treated MRic<sup>−/−</sup> and MRic<sup>+/+</sup> mice (Fig. 7F). In MRic<sup>−/−</sup> mice, insulin caused an ~65% reduction in GSK-3 activity compared to activity in saline-injected mice of the same genotype (6.18 ± 0.32 pmol/min/mg protein versus 2.16 ± 0.18 pmol/min/mg protein; n = 3 per group; P < 0.0004). Consistent with the increase in the level of GSK-3 phosphorylated at Ser21/9 (Fig. 2D and G), the GSK-3 activity in saline-injected MRic<sup>−/−</sup> mice was reduced by ~35% compared to the activity in saline-injected MRic<sup>+/+</sup> mice (4.06 ± 0.29 pmol/min/mg protein versus 6.18 ± 0.18 pmol/min/mg protein; n = 3 per group; P < 0.009). Insulin-injected mice of both genotypes showed similar GSK-3 activities (2.16 ± 0.18 pmol/min/mg protein in MRic<sup>−/−</sup> mice and 2.4 ± 0.18 pmol/min/mg protein in MRic<sup>+/+</sup> mice; n = 3 per group).

**DISCUSSION**

We have used muscle-specific rictor knockout mice to show that the loss of rictor and presumably functional mTORC2 plays an important role in insulin signaling in muscle. In the absence of rictor, there is a dramatic decrease in Akt phosphorylation at Ser473 in response to insulin. Furthermore, skeletal muscle from MRic<sup>−/−</sup> mice exhibits both impaired insulin-mediated glucose uptake and increased glycogen synthase activity in the basal state. Our findings demonstrate that rictor, either as a component of mTORC2 or independently, is essential for the proper control of glucose uptake and the conversion of glucose into glycogen in skeletal muscle.

Since Akt activity is directly required for insulin-stimulated glucose uptake (8), it is possible that impaired Akt Ser473 phosphorylation affects the phosphorylation of a direct target of Akt that regulates redistribution of GLUT4 from intracellular sites to the cell surface (21, 56). In MRic<sup>−/−</sup> muscles, impaired phosphorylation of Akt Ser473 leads to diminished phosphorylation of AS160, an inhibitor of basal GLUT4 exocytosis (18). The Akt-mediated AS160 phosphorylation and consequent inhibition of Rab-GAP (GTPase activating protein) activity of AS160 have been proposed as a mechanism to increase insulin-mediated GLUT4 exocytosis (42). In addition, MRic<sup>−/−</sup> muscles could also have a defect in mTORC2-mediated regulation of the actin cytoskeleton (24, 43) contributing to reduced glucose uptake, as insulin-stimulated glucose uptake is an actin cytoskeleton-dependent process (18). Future experiments will examine exactly where the defect in insulin-stimulated glucose transport occurs in MRic<sup>−/−</sup> muscles.

In MRic<sup>−/−</sup> muscle, basal glycogen synthase activity is up-regulated, reaching levels comparable to that of wild-type muscles after insulin stimulation. This effect can be mediated by increased expression of glycogen synthase, increased basal uptake of glucose, and changes in the phosphorylation state of glycogen synthase. Because there is no change in either total glycogen synthase levels or basal glucose uptake in MRic<sup>−/−</sup> muscles, it is unlikely that the observed increase in glycogen synthase activity occurs through increased expression or allosteric activation by G-6P. The phosphorylation of glycogen synthase at a GSK-3/PP1-regulated site (Ser641) was decreased in MRic<sup>−/−</sup> muscles under basal conditions. In vivo, this could be explained partly by decreased GSK-3 activity (Fig. 7F) caused by increased phosphorylation at the inhibitory site Ser21/9 in GSK-3 α/β (Fig. 2D and G). However, under ex vivo conditions the basal level of GSK-3 phosphorylation and presumably GSK-3 activity was unaltered (Fig. 4B and C). Interestingly, the basal activity and the phosphorylation of glycogen synthase showed a significant elevation and reduction, respectively, compared to levels for the wild type. This inconsistency suggested that a mechanism independent of GSK-3 might be responsible for the observed changes in basal glycogen synthase activity.

Further investigation into the increased basal activation of glycogen synthase led us to discover that PP1 activity was increased in glycogen pellets from MRic<sup>−/−</sup> muscles. The increased PP1 activity correlates with a decreased level of phosphorylated glycogen synthase and suggests that PP1-mediated dephosphorylation of glycogen synthase is responsible for the increase in basal glycogen synthase activity in MRic<sup>−/−</sup> muscle. The mechanism by which loss of rictor results in increased PP1 activity in muscle glycogen pellets is not known. In skeletal muscle, R<sub>GIL</sub> (51) and PP1β (5) have been shown to be the most abundant glycogen targeting subunit and PP1 isoform, respectively. PP1β is also reported to be the major R<sub>GIL</sub>-associated PP1 isoform (7, 13). Loss of R<sub>GIL</sub> expression in mice causes an ~70% reduction in basal insulin glycogen synthase activity and an ~50% reduction in PP1 activity in skeletal muscle (13). PTG is the other known subunit targeting PP1 to glycogen in skeletal muscle. Heterozygous PTG knockout mice exhibit reduced basal glycogen synthase activity (11). We have been unsuccessful in detecting PTG in muscle extracts and glycogen pellet. Since the levels of PP1α and PP1β were not changed in the glycogen pellets from MRic<sup>−/−</sup> muscle, it is likely that yet-to-be-defined modifications of glycogen-associated PP1 lead to enhanced specific activity of the enzyme.

Despite impaired glucose transport and altered glycogen synthase activity in skeletal muscle, the MRic<sup>−/−</sup> mice displayed only a mild impairment in glucose tolerance (Fig. 5C). Such discrepancies have been observed with different mouse models in which insulin signaling proteins and enzymes of glucose metabolism had been deleted. For example, muscle-specific insulin receptor knockout mice (6) and mice with a whole-body knockout of glycogen synthase 1 (muscle-specific isoform) (37) have defects in muscle glucose transport and glycogen synthase activity, respectively, yet both are glucose tolerant. In these mice, compensatory responses in the liver have been proposed to maintain normal glucose homeostasis. Supporting this notion, the liver-specific insulin receptor knockout mice have impaired glucose tolerance due to a lack of control of hepatic glucose production by insulin (33).

Interestingly, we observed a modest increase in basal levels of Akt phosphorylation at Thr308 in MRic<sup>−/−</sup> muscles. There are several possible causes for increased basal Akt Thr308 phosphorylation. First, since the phosphorylation of Akt at Thr308 by PDK1 is a PI3P (phosphatidylinositol-3,4,5-trisphosphate)-dependent process, the increased phosphorylation may simply reflect increased signaling due to PI3P levels in MRic<sup>−/−</sup> muscles. Second, both the contraction of rat skeletal muscle (41) and increased cyclic AMP are known to induce phosphorylation of Akt at Thr308 (15). Thus, MRic<sup>−/−</sup> mus-
cules may have an increased response to the contraction of myotubes or increased sensitivity to a circulating factor in fasted mice that induces cyclic AMP in muscles. Consistent with the increase in basal levels of Akt Thr308 phosphorylation, we also observed increased basal phosphorylation of GSK-3 and S6K1 in MRic−/− muscles. The phosphorylation of both Ser9 and Ser21 of GSK-3α/β has also been reported to be mediated by PKA in HEK293 cells and NIH 3T3 cells (14).

Although phosphorylation of Akt at Ser473 in response to insulin was abolished completely in MRic−/− muscles, there was no effect on insulin-stimulated Akt Thr308 phosphorylation. This is in agreement with previous observations for rictor null MEFs and embryos (48) but contradicts another report that Ser473 phosphorylation is a determinant of Thr308 phosphorylation (44). Diminished or absent Ser473 phosphorylation reduces Akt activity when measured in vitro (48). Previous work has shown that loss of Ser473 phosphorylation did not affect Akt signaling to some direct substrates, including TSC2 and GSK-3 (16, 48). Our study confirms these observations.

TSC2 phosphorylation by Akt in response to insulin is required to activate mTORC1 (22). Since insulin-induced mTORC1 activation was normal, as indicated by unaltered S6K1 Thr389 phosphorylation, there did not appear to be a defect in Akt activation was normal, as indicated by unaltered S6K1 Thr389 phosphorylation, there did not appear to be a defect in Akt activation. Since insulin-induced mTORC1 map to different human chromosomess: sequence, expression and gene localisation of protein serine/threonine phosphatase 1 beta (PP1CB). Biochim. Biophys. Acta 1226:212–218.


